Anindo Saha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anindo Saha has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
- Henkjan Huisman
Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen
8 shared publications - Joeran Sander Bosma
Diagnostic Image Analysis Group, Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
5 shared publications - Derya Yakar
Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
4 shared publications - Maarten de Rooij
Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
4 shared publications Henkjan Huisman
3 shared publications- Jasper J. Twilt
Minimally Invasive Image-Guided Intervention Center, Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
3 shared publications
Latest Publications
- 1 October 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 321 (1)
Artificial Intelligence for Prostate Cancer Detection and Screening on MRI in Global Populations: The SCARLET-1 Study
In this study of 22,445 prostate MRI examinations from 22 countries, an AI system’s performance was comparable to radiology readings for prostate cancer detection in external diagnostic and screening datasets.
- 1 October 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 321 (1)
Artificial Intelligence for Prostate Cancer Detection and Screening on MRI in Global Populations: The SCARLET-1 Study
In this study of 22,445 prostate MRI examinations from 22 countries, an AI system’s performance was comparable to radiology readings for prostate cancer detection in external diagnostic and screening datasets.
- Open Access
- 21 November 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 199, 111321
Scalable Clinical Annotation with Location Evidence (SCALE)
- 21 November 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 199, 111321
Open AccessScalable Clinical Annotation with Location Evidence (SCALE)
- 1 January 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 7 (1) , e240078
Development and Validation of a Deep Learning Model Based on MRI and Clinical Characteristics to Predict Risk of Prostate Cancer Progression
The proposed deep learning model based on MRI and clinical characteristics showed good performance in predicting progression from low-risk prostate cancer to clinically significant prostate cancer.
- 1 January 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 7 (1) , e240078
Development and Validation of a Deep Learning Model Based on MRI and Clinical Characteristics to Predict Risk of Prostate Cancer Progression
The proposed deep learning model based on MRI and clinical characteristics showed good performance in predicting progression from low-risk prostate cancer to clinically significant prostate cancer.
- 5 October 2024
- Published by Springer Nature
- p. 148-162
Deformable MRI Sequence Registration for AI-Based Prostate Cancer Diagnosis
- 5 October 2024
- Published by Springer Nature
- p. 148-162
Deformable MRI Sequence Registration for AI-Based Prostate Cancer Diagnosis
- Top Cited Papers
- 12 June 2024
- Published by Elsevier in The Lancet Oncology
- Vol. 25 (7) , 879-887
Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study
- 12 June 2024
- Published by Elsevier in The Lancet Oncology
- Vol. 25 (7) , 879-887
Top Cited PapersArtificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study
- Open Access
- 1 September 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 5 (5) , e230031
Semisupervised Learning with Report-guided Pseudo Labels for Deep Learning–based Prostate Cancer Detection Using Biparametric MRI
To evaluate a novel method of semisupervised learning (SSL) guided by automated sparse information from diagnostic reports to leverage additional data for deep learning–based malignancy detection in patients with clinically significant prostate cancer. This retrospective study included 7756 prostate MRI examinations (6380 patients) performed between January 2014 and December 2020 for model development. An SSL method, report-guided SSL (RG-SSL), was developed for detection of clinically significant prostate cancer using biparametric MRI. RG-SSL, supervised learning (SL), and state-of-the-art SSL methods were trained using 100, 300, 1000, or 3050 manually annotated examinations. Performance on detection of clinically significant prostate cancer by RG-SSL, SL, and SSL was compared on 300 unseen examinations from an external center with a histopathologically confirmed reference standard. Performance was evaluated using receiver operating characteristic (ROC) and free-response ROC analysis. P values for performance differences were generated with a permutation test. At 100 manually annotated examinations, mean examination-based diagnostic area under the ROC curve (AUC) values for RG-SSL, SL, and the best SSL were 0.86 ± 0.01 (SD), 0.78 ± 0.03, and 0.81 ± 0.02, respectively. Lesion-based detection partial AUCs were 0.62 ± 0.02, 0.44 ± 0.04, and 0.48 ± 0.09, respectively. Examination-based performance of SL with 3050 examinations was matched by RG-SSL with 169 manually annotated examinations, thus requiring 14 times fewer annotations. Lesion-based performance was matched with 431 manually annotated examinations, requiring six times fewer annotations. RG-SSL outperformed SSL in clinically significant prostate cancer detection and achieved performance similar to SL even at very low annotation budgets. Keywords: Annotation Efficiency, Computer-aided Detection and Diagnosis, MRI, Prostate Cancer, Semisupervised Deep Learning Supplemental material is available for this article. Published under a CC BY 4.0 license.
- 1 September 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 5 (5) , e230031
Open AccessSemisupervised Learning with Report-guided Pseudo Labels for Deep Learning–based Prostate Cancer Detection Using Biparametric MRI
To evaluate a novel method of semisupervised learning (SSL) guided by automated sparse information from diagnostic reports to leverage additional data for deep learning–based malignancy detection in patients with clinically significant prostate cancer. This retrospective study included 7756 prostate MRI examinations (6380 patients) performed between January 2014 and December 2020 for model development. An SSL method, report-guided SSL (RG-SSL), was developed for detection of clinically significant prostate cancer using biparametric MRI. RG-SSL, supervised learning (SL), and state-of-the-art SSL methods were trained using 100, 300, 1000, or 3050 manually annotated examinations. Performance on detection of clinically significant prostate cancer by RG-SSL, SL, and SSL was compared on 300 unseen examinations from an external center with a histopathologically confirmed reference standard. Performance was evaluated using receiver operating characteristic (ROC) and free-response ROC analysis. P values for performance differences were generated with a permutation test. At 100 manually annotated examinations, mean examination-based diagnostic area under the ROC curve (AUC) values for RG-SSL, SL, and the best SSL were 0.86 ± 0.01 (SD), 0.78 ± 0.03, and 0.81 ± 0.02, respectively. Lesion-based detection partial AUCs were 0.62 ± 0.02, 0.44 ± 0.04, and 0.48 ± 0.09, respectively. Examination-based performance of SL with 3050 examinations was matched by RG-SSL with 169 manually annotated examinations, thus requiring 14 times fewer annotations. Lesion-based performance was matched with 431 manually annotated examinations, requiring six times fewer annotations. RG-SSL outperformed SSL in clinically significant prostate cancer detection and achieved performance similar to SL even at very low annotation budgets. Keywords: Annotation Efficiency, Computer-aided Detection and Diagnosis, MRI, Prostate Cancer, Semisupervised Deep Learning Supplemental material is available for this article. Published under a CC BY 4.0 license.
- Open Access
Uncertainty-Aware Semi-Supervised Learning for Prostate MRI Zonal Segmentation
Quality of deep convolutional neural network predictions strongly depends on the size of the training dataset and the quality of the annotations. Creating annotations, especially for 3D medical image segmentation, is time-consuming and requires expert knowledge. We propose a novel semi-supervised learning (SSL) approach that requires only a relatively small number of annotations while being able to use the remaining unlabeled data to improve model performance. Our method uses a pseudo-labeling technique that employs recent deep learning uncertainty estimation models. By using the estimated uncertainty, we were able to rank pseudo-labels and automatically select the best pseudo-annotations generated by the supervised model. We applied this to prostate zonal segmentation in T2-weighted MRI scans. Our proposed model outperformed the semi-supervised model in experiments with the ProstateX dataset and an external test set, by leveraging only a subset of unlabeled data rather than the full collection of 4953 cases, our proposed model demonstrated improved performance. The segmentation dice similarity coefficient in the transition zone and peripheral zone increased from 0.835 and 0.727 to 0.852 and 0.751, respectively, for fully supervised model and the uncertainty-aware semi-supervised learning model (USSL). Our USSL model demonstrates the potential to allow deep learning models to be trained on large datasets without requiring full annotation. Our code is available at https://github.com/DIAGNijmegen/prostateMR-USSL.
Open AccessUncertainty-Aware Semi-Supervised Learning for Prostate MRI Zonal Segmentation
Quality of deep convolutional neural network predictions strongly depends on the size of the training dataset and the quality of the annotations. Creating annotations, especially for 3D medical image segmentation, is time-consuming and requires expert knowledge. We propose a novel semi-supervised learning (SSL) approach that requires only a relatively small number of annotations while being able to use the remaining unlabeled data to improve model performance. Our method uses a pseudo-labeling technique that employs recent deep learning uncertainty estimation models. By using the estimated uncertainty, we were able to rank pseudo-labels and automatically select the best pseudo-annotations generated by the supervised model. We applied this to prostate zonal segmentation in T2-weighted MRI scans. Our proposed model outperformed the semi-supervised model in experiments with the ProstateX dataset and an external test set, by leveraging only a subset of unlabeled data rather than the full collection of 4953 cases, our proposed model demonstrated improved performance. The segmentation dice similarity coefficient in the transition zone and peripheral zone increased from 0.835 and 0.727 to 0.852 and 0.751, respectively, for fully supervised model and the uncertainty-aware semi-supervised learning model (USSL). Our USSL model demonstrates the potential to allow deep learning models to be trained on large datasets without requiring full annotation. Our code is available at https://github.com/DIAGNijmegen/prostateMR-USSL.
- Top Cited PapersOpen Access
- 1 October 2021
- Published by Elsevier in Medical Image Analysis
- Vol. 73, 102155
End-to-end prostate cancer detection in bpMRI via 3D CNNs: Effects of attention mechanisms, clinical priori and decoupled false positive reduction
- 1 October 2021
- Published by Elsevier in Medical Image Analysis
- Vol. 73, 102155
Top Cited PapersOpen AccessEnd-to-end prostate cancer detection in bpMRI via 3D CNNs: Effects of attention mechanisms, clinical priori and decoupled false positive reduction
- Open Access
Encoding Clinical Priori in 3D Convolutional Neural Networks for Prostate Cancer Detection in bpMRI
We hypothesize that anatomical priors can be viable mediums to infuse domain-specific clinical knowledge into state-of-the-art convolutional neural networks (CNN) based on the U-Net architecture. We introduce a probabilistic population prior which captures the spatial prevalence and zonal distinction of clinically significant prostate cancer (csPCa), in order to improve its computer-aided detection (CAD) in bi-parametric MR imaging (bpMRI). To evaluate performance, we train 3D adaptations of the U-Net, U-SEResNet, UNet++ and Attention U-Net using 800 institutional training-validation scans, paired with radiologically-estimated annotations and our computed prior. For 200 independent testing bpMRI scans with histologically-confirmed delineations of csPCa, our proposed method of encoding clinical priori demonstrates a strong ability to improve patient-based diagnosis (upto 8.70% increase in AUROC) and lesion-level detection (average increase of 1.08 pAUC between 0.1-10 false positives per patient) across all four architectures.
Open AccessEncoding Clinical Priori in 3D Convolutional Neural Networks for Prostate Cancer Detection in bpMRI
We hypothesize that anatomical priors can be viable mediums to infuse domain-specific clinical knowledge into state-of-the-art convolutional neural networks (CNN) based on the U-Net architecture. We introduce a probabilistic population prior which captures the spatial prevalence and zonal distinction of clinically significant prostate cancer (csPCa), in order to improve its computer-aided detection (CAD) in bi-parametric MR imaging (bpMRI). To evaluate performance, we train 3D adaptations of the U-Net, U-SEResNet, UNet++ and Attention U-Net using 800 institutional training-validation scans, paired with radiologically-estimated annotations and our computed prior. For 200 independent testing bpMRI scans with histologically-confirmed delineations of csPCa, our proposed method of encoding clinical priori demonstrates a strong ability to improve patient-based diagnosis (upto 8.70% increase in AUROC) and lesion-level detection (average increase of 1.08 pAUC between 0.1-10 false positives per patient) across all four architectures.
- Open Access
End-to-end Prostate Cancer Detection in bpMRI via 3D CNNs: Effects of Attention Mechanisms, Clinical Priori and Decoupled False Positive Reduction
We present a multi-stage 3D computer-aided detection and diagnosis (CAD) model for automated localization of clinically significant prostate cancer (csPCa) in bi-parametric MR imaging (bpMRI). Deep attention mechanisms drive its detection network, targeting salient structures and highly discriminative feature dimensions across multiple resolutions. Its goal is to accurately identify csPCa lesions from indolent cancer and the wide range of benign pathology that can afflict the prostate gland. Simultaneously, a decoupled residual classifier is used to achieve consistent false positive reduction, without sacrificing high sensitivity or computational efficiency. In order to guide model generalization with domain-specific clinical knowledge, a probabilistic anatomical prior is used to encode the spatial prevalence and zonal distinction of csPCa. Using a large dataset of 1950 prostate bpMRI paired with radiologically-estimated annotations, we hypothesize that such CNN-based models can be trained to detect biopsy-confirmed malignancies in an independent cohort. For 486 institutional testing scans, the 3D CAD system achieves 83.69$\pm$5.22% and 93.19$\pm$2.96% detection sensitivity at 0.50 and 1.46 false positive(s) per patient, respectively, with 0.882$\pm$0.030 AUROC in patient-based diagnosis $-$significantly outperforming four state-of-the-art baseline architectures (U-SEResNet, UNet++, nnU-Net, Attention U-Net) from recent literature. For 296 external biopsy-confirmed testing scans, the ensembled CAD system shares moderate agreement with a consensus of expert radiologists (76.69%; $kappa$ $=$ 0.51$\pm$0.04) and independent pathologists (81.08%; $kappa$ $=$ 0.56$\pm$0.06); demonstrating strong generalization to histologically-confirmed csPCa diagnosis.Open AccessEnd-to-end Prostate Cancer Detection in bpMRI via 3D CNNs: Effects of Attention Mechanisms, Clinical Priori and Decoupled False Positive Reduction
We present a multi-stage 3D computer-aided detection and diagnosis (CAD) model for automated localization of clinically significant prostate cancer (csPCa) in bi-parametric MR imaging (bpMRI). Deep attention mechanisms drive its detection network, targeting salient structures and highly discriminative feature dimensions across multiple resolutions. Its goal is to accurately identify csPCa lesions from indolent cancer and the wide range of benign pathology that can afflict the prostate gland. Simultaneously, a decoupled residual classifier is used to achieve consistent false positive reduction, without sacrificing high sensitivity or computational efficiency. In order to guide model generalization with domain-specific clinical knowledge, a probabilistic anatomical prior is used to encode the spatial prevalence and zonal distinction of csPCa. Using a large dataset of 1950 prostate bpMRI paired with radiologically-estimated annotations, we hypothesize that such CNN-based models can be trained to detect biopsy-confirmed malignancies in an independent cohort. For 486 institutional testing scans, the 3D CAD system achieves 83.69$\pm$5.22% and 93.19$\pm$2.96% detection sensitivity at 0.50 and 1.46 false positive(s) per patient, respectively, with 0.882$\pm$0.030 AUROC in patient-based diagnosis $-$significantly outperforming four state-of-the-art baseline architectures (U-SEResNet, UNet++, nnU-Net, Attention U-Net) from recent literature. For 296 external biopsy-confirmed testing scans, the ensembled CAD system shares moderate agreement with a consensus of expert radiologists (76.69%; $kappa$ $=$ 0.51$\pm$0.04) and independent pathologists (81.08%; $kappa$ $=$ 0.56$\pm$0.06); demonstrating strong generalization to histologically-confirmed csPCa diagnosis.